FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Contrasting decisions by FDA and the European Medicines Agency on the fate of GlaxoSmithKline’s Avandia reflect not so much a divergence of scientific opinion between the two regulators, but rather differences in how they chose to manage the drug’s cardiovascular risks and the tools available for doing so.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet